Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update Clearside Biomedical Q3 2023 Financial Results and Corporate Update Call Form 10-Q View All News Releases Feb 7 2024 Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering Dec 14 2023 Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD Nov 13 2023 Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update View All Events More events are coming soon. View All Stock Quote Change Volume 52 Week High 52 Week Low Feb 28, 2024 8:39 AM EST Data Provided by Refinitiv. Minimum 15 minutes delayed.